5/6/2013

AltheRx Pharmaceuticals secured $15 million in its latest funding round. The Exton, Pa.-based firm plans to use the money to bring Solabegron, its lead drug candidate for overactive bladder, into late-stage trials. AltheRx also appointed Jim Bennethum, former executive vice president of Becker Ventures, as its new CEO.

Related Summaries